Testosterone therapy for high-risk prostate cancer survivors: a systematic review and meta-analysis

Fiona Teeling*, Mr Nicholas Raison, Mr Majed Shabbir, Mr Tet Yap, Professor Prokar Dasgupta, Mr Kamran Ahmed

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

14 Citations (Scopus)
291 Downloads (Pure)

Abstract

A systematic review and meta-analysis was performed to determine the relationship between testosterone therapy and risk of recurrence in testosterone-deficient survivors of curatively treated high-risk prostate cancer. Primary outcome was the risk of biochemical recurrence (BCR) in 109 high-risk patients in 13 included studies (1997-2017). Biochemical and symptomatic effects of therapy were also reviewed. The BCR rate was 0.00 (0.00-0.05), lower than the expected rate for high-risk prostate cancer survivors, suggesting that testosterone therapy may not increase their BCR risk. However, this is uncertain as the available evidence is of very low quality. Testosterone therapy remains investigational in this group.

Original languageEnglish
Pages (from-to)16-23
Number of pages8
JournalUrology
Volume126
Early online date21 Sept 2018
DOIs
Publication statusPublished - Apr 2019

Keywords

  • Testosterone therapy
  • Prostate cancer
  • Biochemical recurrence

Fingerprint

Dive into the research topics of 'Testosterone therapy for high-risk prostate cancer survivors: a systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this